Clinical Trial Update: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) in 7- to 17-year-olds; the study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Meningococcal Meningitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING